Significance of INHBA expression in human colorectal cancer

Okano,Miho; Yamamoto,Hirofumi; Ohkuma,Hisataka; Kano,Yoshihiro; Kim,Hirotoshi; Nishikawa,Shimpei; Konno,Masamitsu; Kawamoto,Koichi; Haraguchi,Naotsugu; Takemasa,Ichiro; Mizushima,Tsunekazu; Ikeda,Masataka; Yokobori,Takehiko; Mimori,Koshi; Sekimoto,Mitsugu; Doki,Yuichiro; Mori,Masaki; Ishii,Hideshi

doi:10.3892/or.2013.2761

Significance of INHBA expression in human colorectal cancer

Authors:
- Miho Okano
- Hirofumi Yamamoto
- Hisataka Ohkuma
- Yoshihiro Kano
- Hirotoshi Kim
- Shimpei Nishikawa
- Masamitsu Konno
- Koichi Kawamoto
- Naotsugu Haraguchi
- Ichiro Takemasa
- Tsunekazu Mizushima
- Masataka Ikeda
- Takehiko Yokobori
- Koshi Mimori
- Mitsugu Sekimoto
- Yuichiro Doki
- Masaki Mori
- Hideshi Ishii
View Affiliations

Affiliations: Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka 565-0871, Japan, Department of Frontier Science for Cancer and Chemotherapy, Graduate School of Medicine, Osaka University, Suita, Osaka 565-0871, Japan, Department of Surgery, Kyushu University Beppu Hospital, Oita 874-0838, Japan
Published online on: October 1, 2013 https://doi.org/10.3892/or.2013.2761
Pages: 2903-2908

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Inhibin β A (INHBA) is a member of the transforming growth factor β (TGF-β) superfamily. INHBA expression is associated with several types of human cancers; however, its significance in colorectal cancer (CRC) is not fully understood. INHBA expression was studied in 126 primary CRC samples and 4 CRC cell lines. Cell growth was assessed after inhibition of INHBA expression or after exogenous overexpression of INHBA in CRC tissues. INHBA expression was significantly higher in CRC tissues when compared to that in the corresponding normal tissues (P<0.001). Patients in the high expression group showed a poorer overall survival rate when compared to those in the low expression group (P<0.001); the present study did not evaluate for an independent prognostic factor but showed the significance of lymph node metastasis as an independent prognostic factor. The present study suggests that INHBA is useful as a predictive marker for prognosis in CRC patients.

View Figures

View References

1	Kohno SI, Luo C, Nawa A, et al: Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus. Cancer Gene Ther. 14:918–926. 2007. View Article : Google Scholar
2	Hermsen M, Postma C, Baak J, et al: Colorectal adenoma to carcinoma progression follows multiple pathways of chromosomal instability. Gastroenterology. 123:1109–1119. 2002. View Article : Google Scholar : PubMed/NCBI
3	Leslie A, Pratt NR, Gillespie K, et al: Mutations of APC, K-ras, and p53 are associated with specific chromosomal aberrations in colorectal adenocarcinomas. Cancer Res. 63:4656–4661. 2003.PubMed/NCBI
4	Gaddy-Kurten D, Tsuchida K and Vale W: Activins and the receptor serine kinase superfamily. Recent Prog Horm Res. 50:109–129. 1995.
5	Vale W, Rivier C, Hsueh A, et al: Chemical and biological characterization of the inhibin family of protein hormones. Recent Prog Horm Res. 44:1–34. 1988.PubMed/NCBI
6	Lorenzen JR, Channing CP and Schwartz NB: Partial characterization of FSH suppressing activity (folliculostatin) in porcine follicular fluid using the metestrous rat as an in vivo bioassay model. Biol Reprod. 19:635–640. 1978. View Article : Google Scholar : PubMed/NCBI
7	Asashima M, Ariizumi T and Malacinski GM: In vitro control of organogenesis and body patterning by activin during early amphibian development. Comp Biochem Physiol B Biochem Mol Biol. 126:169–178. 2000. View Article : Google Scholar : PubMed/NCBI
8	Yoshinaga K, Mimori K, Yamashita K, Utsunomiya T, Inoue H and Mori M: Clinical significance of the expression of activin A in esophageal carcinoma. Int J Oncol. 22:75–80. 2003.PubMed/NCBI
9	Kleeff J, Ishiwata T, Friess H, Büchler MW and Korc M: Concomitant over-expression of activin/inhibin β subunits and their receptors in human pancreatic cancer. Int J Cancer. 77:860–868. 1998.PubMed/NCBI
10	Thomas TZ, Wang H, Niclasen P, et al: Expression and localization of activin subunits and follistatins in tissues from men with high grade prostate cancer. J Clin Endocrinol Metab. 82:3851–3858. 1997. View Article : Google Scholar : PubMed/NCBI
11	Woodruff TK: Role of inhibins and activins in ovarian cancer. Cancer Treat Res. 107:293–302. 2002.PubMed/NCBI
12	Zheng W, Luo MP, Welt C, et al: Imbalanced expression of inhibin and activin subunits in primary epithelial ovarian cancer. Gynecol Oncol. 69:23–31. 1998. View Article : Google Scholar : PubMed/NCBI
13	Petraglia F, Florio P, Luisi S, et al: Expression and secretion of inhibin and activin in normal and neoplastic uterine tissues. High levels of serum activin A in women with endometrial and cervical carcinoma. J Clin Endocrinol Metab. 83:1194–1200. 1998.PubMed/NCBI
14	Miyoshi N, Ishii H, Sekimoto M, Doki Y and Mori M: RGS16 is a marker for prognosis in colorectal cancer. Ann Surg Oncol. 16:3507–3514. 2009. View Article : Google Scholar
15	Sobin LH and Fleming ID: TNM Classification of Malignant Tumors. 5th edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer. 80:1803–1804. 1997. View Article : Google Scholar : PubMed/NCBI
16	Mimori K, Mori M, Shiraishi T, et al: Clinical significance of tissue inhibitor of metalloproteinase expression in gastric carcinoma. Br J Cancer. 76:531–536. 1997. View Article : Google Scholar : PubMed/NCBI
17	Mori M, Staniunas RJ, Barnard GF, et al: The significance of carbonic anhydrase expression in human colorectal cancer. Gastroenterology. 105:820–826. 1993.PubMed/NCBI
18	Burger HG and Igarashi M: Inhibin: definition and nomenclature, including related substances. Endocrinology. 122:1701–1702. 1988. View Article : Google Scholar : PubMed/NCBI
19	Murata M, Eto Y, Shibai H, Sakai M and Muramatsu M: Erythroid differentiation factor is encoded by the same mRNA as that of the inhibin β_A chain. Proc Natl Acad Sci USA. 85:2434–2438. 1988. View Article : Google Scholar : PubMed/NCBI
20	Brown CW, Houston-Hawkins DE, Woodruff TK and Matzuk MM: Insertion of Inhbb into the Inhba locus rescues the Inhba-null phenotype and reveals new activin functions. Nat Genet. 25:453–457. 2000. View Article : Google Scholar : PubMed/NCBI
21	Wolpin BM and Mayer RJ: Systemic treatment of colorectal cancer. Gastroenterology. 134:1296–1310. 2008. View Article : Google Scholar : PubMed/NCBI
22	Kornmann M, Formentini A, Ette C, et al: Prognostic factors influencing the survival of patients with colon cancer receiving adjuvant 5-FU treatment. Eur J Surg Oncol. 34:1316–1321. 2008. View Article : Google Scholar : PubMed/NCBI
23	Bathe OF, Dowden S, Sutherland F, et al: Phase II study of neoadjuvant 5-FU + leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinoma. BMC Cancer. 4:322004.
24	Lacy AM, Garcia-Valdecasas JC, Delgado S, Castells A, Taurá P, Piqué JM and Visa J: Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial. Lancet. 359:2224–2229. 2002. View Article : Google Scholar : PubMed/NCBI
25	Weeks JC, Nelson H, Gelber S, et al: Short-term quality-of-life outcomes following laparoscopic-assisted colectomy vs open colectomy for colon cancer: a randomized trial. JAMA. 287:321–328. 2002. View Article : Google Scholar : PubMed/NCBI
26	Clinical Outcomes of Surgical Therapy Study Group. A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med. 350:2050–2059. 2004. View Article : Google Scholar
27	Jayne DG, Guillou PJ, Thorpe H, et al: Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC Trial Group. J Clin Oncol. 25:3061–3068. 2007.PubMed/NCBI